You have read all your free articles, to continue reading subscribe to read the rest of this content.
Follicum has announced that the European Patent Office (EPO) has approved a patent which refers to the company's novel peptides that are being developed to treat diabetes. The approval follows the previous provisional approval by the EPO announced on March 20, 2020. The approval provides protectiAlready a subscriber Login You…
The company's MOB-015 has been granted patent protection in China, valid until 2032. MOB-015 is an internally developed topical formulation of terbinafine for the treatment of onychomycosis, currently under clinical development in phase 3. MOB-015’s patent protection thus covers the key marketsAlready a subscriber Login You have read all your…
Ultimovacs has received a Notice of Intention to Grant from the European Patent Office (EPO) concerning its European Patent application on the use of vaccine-checkpoint inhibitor combinations to treat cancer. Subject to grant formalities including translations and fee disbursement, the European pAlready a subscriber Login You have read all your…
Sigrid Therapeutics has announced that the European Patent Office has granted the company patent titled “A porous silica material for use as a pharmaceutical or dietary active ingredient”. The patent supports use of Sigrid’s mesoporous silica particles (MSP)-based device which consists of pAlready a subscriber Login You have read all…
